VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 128 filers reported holding VERVE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,927,983 | -38.8% | 296,228 | -13.4% | 0.00% | -100.0% |
| Q2 2023 | $6,413,515 | +84.7% | 342,054 | +42.0% | 0.00% | – |
| Q1 2023 | $3,472,639 | +85.1% | 240,821 | +148.4% | 0.00% | – |
| Q4 2022 | $1,875,847 | -58.7% | 96,943 | -26.7% | 0.00% | -100.0% |
| Q3 2022 | $4,545,000 | +50.5% | 132,326 | -33.0% | 0.00% | – |
| Q2 2022 | $3,020,000 | -38.9% | 197,546 | -8.9% | 0.00% | -100.0% |
| Q1 2022 | $4,945,000 | +682.4% | 216,772 | +1163.5% | 0.00% | – |
| Q4 2021 | $632,000 | +129.0% | 17,156 | +191.3% | 0.00% | – |
| Q3 2021 | $276,000 | +85.2% | 5,889 | +138.6% | 0.00% | – |
| Q2 2021 | $149,000 | – | 2,468 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |